Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 16Terminated 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 23Myeloid 17Sarcoma 9Gastrointestinal 7Lymphoid 6Tumor-Agnostic 2Other solid neoplasm 2Dermatologic 2Thoracic 1Head & Neck 1CNS 1

Conditions

Mesothelioma 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Imatinib Mesylate × Thoracic × Clear all
NCT00551252 2007-10-30

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

Gruppo Italiano MEsotelioma

Phase 2 Unknown
56 enrolled
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡